Lumigan

DRUG3 trials

Sponsors

Sun Pharmaceutical Industries Limited, AbbVie

Conditions

Ocular HypertensionOpen Angle GlaucomaOpen-Angle GlaucomaOpen-angle Glaucoma

Phase 1

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

RecruitingNCT04499248

AbbVieOcular Hypertension, Open-angle Glaucoma

Start: 2020-11-16End: 2029-02-01Target: 96Updated: 2026-03-23

Phase 3

A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension

WithdrawnNCT03927443

Sun Pharmaceutical Industries LimitedOcular Hypertension, Open Angle Glaucoma

Start: 2019-06-10End: 2019-07-08Updated: 2021-11-19

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

CompletedNCT04285580

AbbVieOcular Hypertension, Open-Angle Glaucoma

Start: 2020-06-11End: 2022-05-14Updated: 2023-06-08

Related Papers

Single Administration of Bimatoprost Implant: Effects on 24-Hour Intraocular Pressure and 1-Year Outcomes.

2023-06-1912 citations